Protocol Ledger

NCT03161028 · Phase II · COMPLETED

Lipoic Acid for Progressive Multiple Sclerosis (MS)

Interventional Phase II clinical trial protocol NCT03161028 sponsored by VA Office of Research and Development in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-08-17 Enrollment: 115 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03161028
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)115 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03161028
Protocol FieldVerified Registry Value
NCT IdentifierNCT03161028
Consolidated Lead SponsorVA Office of Research and Development
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment115 participants (ACTUAL)
Registered Start Date2018-08-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03161028
Hospital Research SiteLocationSite Profile
University of Alabama at BirminghamBirmingham, ALOpen Hospital Dossier ->
University of Colorado Anschutz Medical CampusAurora, COOpen Hospital Dossier ->
Huntsman Cancer Institute at University of UtahSalt Lake City, UTOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI